Posted by Michael Wonder on 02 Mar 2023
FDA and FTC collaborate to advance competition in the biologic marketplace
2 March 2023 - In 2021 alone, the US spent $256 billion on biologics. Although biologics comprise approximately 3% of prescriptions in the US, these products account for over half of prescription medicine spending.
This is not sustainable for either the patients who need these medicines or for our health care system. That is why the FDA and the Federal Trade Commission have been working together to help advance competition for biologics, including biosimilars and interchangeable biosimilars.
